Skip to main content

Table 1 Baseline characteristics at continuous renal replacement therapy initiation

From: Urine neutrophil gelatinase-associated lipocalin and urine output as predictors of the successful discontinuation of continuous renal replacement therapy in critically ill patients with acute kidney injury

Clinical variables Recovery (n = 22) Non-recovery; CRRT re-initiation (n = 20) Non-recovery; Haemodialysis initiation (n = 12) P-value
Male/female 16/6 (73%/27%) 11/9 (55%/45%) 9/3 (75%/25%) 0.56
Age, years 77 [42–83] 70 [51–81] 68 [30–83] 0.84
BMI, kg/m2 26 [19–35] 27 [19–38] 25 [24–37] 0.45
SOFA, highest value 13 [7–18] 15 [11–19] 13 [8–21] 0,20
APACHE II 27 [18–40] 29 [21–43] 26 [18–38] 0.71
SAPS II 56 [30–75] 65 [44–86] 58 [38–78] 0.10
Hypertension 9 (41%) 11 (55%) 7 (58%) 0.76
Malignity 6 (27%) 10 (50%) 2 (17%) 0.56
CVVH/CVVHD 0/22 (0/100%) 4/16 (20/80%) 0/12 (0/100%) 0.14
RIFLE-F 21 (95%)a 20 (100%) 12 (100%) 0.41
Furosemide, mg/day 0 [0–554] 80 [0–534] 100 [0–480] 0.44d
Mean arterial pressure, mmHg 69 [62–85] 70 [63–93] 78 [59–113] 0.23
Creatinine, μmol/L 186 [84–621] 194 [87–531] 238 [90–765] 0.99
Creatinine clearance, ml/min 19 [7–45] 15 [8–27] 17 [5–26] 0.11
C-Reactive Protein (CRP), mg/L 216 [7–454] 139 [13–266] 108 [34–423] 0.18
Urine output, ml/hour b 18 [0–50] 8 [0–97] 0 [0–52] 0.40d
Urine output, ml/day c 398 [103–1488] 326 [8–1750] 120 [13–2550] 0.23d
Noradrenaline, μg/kg/min 0.35 [0.09–1.26] 0.28 [0.07–1.32] 0.12 [0.02–1.10] 0.35d
Nephrotoxic medicine including contrast. 8 (36%) 12 (60%) 6 (50%) 0.18
Presumed primary cause of AKI:     0.56
 Prerenal 8 (36%) 5 (25%) 2 (17%)
 Sepsis 12 (55%) 13 (65%) 4 (33%)
 Glomerulonephritis 0 0 1 (8%)
 Rhabdomyolysis 1 (4,5%) 1 (5%) 3 (25%)
 Microthrombosis/vasculitis 1 (4,5%) 1 (5%) 2 (17%)
Primary reason for ICU admission:     0.62
 Septic shock/sepsis 9 (41%) 103 (65%) 6 (51%)
 Trauma 1 (5%) 2 (10%) 0
 AKI 5 (23%) 1 (5%) 2 (17%)
 Respiratory failure 4 (18%) 2 (10%) 3 (34%)
 Low cardiac output 3 (14%) 2 (10%) 1 (8%)
Urine-NGAL, μg/L 2645 [279–27,543] 2894 [749–18,537] 3619 [128–30,170] 0.57d
Time, ICU admission to CRRT initiation/study inclusion, days 1 [0–7.4] 2 [0–5.9] 1 [0–12.1] 0.94
  1. P-value was calculated between the recovery and non-recovery (CRRT-re-initiation and haemodialysis) groups. CRRT, continuous renal replacement therapy; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment; APACHE II, Acute Physiology and Chronic Health Evaluation II; CVVH, continuous veno-venous haemofiltration; CVVHD, continuous veno-venous haemodialysis; AKI, acute kidney injury; NGAL, neutrophil gelatinase-associated lipocalin. Categorical variables are expressed as numbers (percentages). Continuous variables are expressed as medians [10–90% quantiles]
  2. a) RIFLE-I was recorded for one patient. b) Mean urine output 6 h before dialysis initiation; if urine output < 5 ml in one hour, then it was recorded as 0 ml. c) Urine output 24 h before CRRT initiation. d) Log10 transformation was used to calculate the p-value
\